Shelton Capital Management Seagen Inc. Transaction History

Shelton Capital Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $1.06 Million - $1.2 Million	5,536 Added 36.02%	20,906 $4.44 Million
Q2 2023 Aug 10, 2023	BUY	$187.64 - $206.25 $136,226 - $149,737	726 Added 4.96%	15,370 $2.96 Million
Q1 2023 May 11, 2023	SELL	$127.59 - $203.08 $160,635 - $255,677	-1,259 Reduced 7.92%	14,644 $2.96 Million
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $87,793 - $115,861	734 Added 4.84%	15,903 $2.29 Million
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $76,560 - $102,491	537 Added 3.67%	15,169 $2.35 Million
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $280,382 - $389,041	2,039 Added 16.19%	14,632 $2.03 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $2.07 Million - $2.67 Million	12,593 New	12,593 $2.21 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

Stay updated on Shelton Capital Management with notifications on news.